Literature DB >> 9118044

Immunohistochemical expression of pi-class glutathione S-transferase is down-regulated in adenocarcinoma of the prostate.

C A Moskaluk1, P H Duray, K H Cowan, M Linehan, M J Merino.   

Abstract

BACKGROUND: Glutathione S-transferase is often up-regulated in neoplastic tissues. A single previous study found a loss of expression associated with carcinogenesis of the prostate.
METHODS: To extend these results, the authors performed immunohistochemical staining for the pi-class of glutathione S-transferase (GSTpi) on 74 archival sequential prostate specimens. The antibody used was derived from rabbits immunized against purified human GSTpi. Paraffin blocks containing both benign tissue and adenocarcinoma were studied.
RESULTS: Heterogeneous expression of GSTpi in benign acini was found in 96% of cases, but GSTpi was not expressed in 95% of invasive adenocarcinomas of the prostate, nor was it expressed in any of the foci of high grade prostatic intraepithelial neoplasia. Basal cells of benign acini showed strong, diffuse staining for GSTpi, whereas the secretory luminal epithelium expressed GSTpi weakly and focally.
CONCLUSIONS: This study confirms the down-regulation of GSTpi in adenocarcinoma of the prostate and shows that the loss of GSTpi expression is a phenotype associated with malignant transformation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9118044     DOI: 10.1002/(sici)1097-0142(19970415)79:8<1595::aid-cncr23>3.0.co;2-s

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  10 in total

1.  Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis.

Authors:  A M De Marzo; V L Marchi; J I Epstein; W G Nelson
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

2.  Identification of a stem cell candidate in the normal human prostate gland.

Authors:  Monika Schmelz; Roland Moll; Ulrike Hesse; Anil R Prasad; Jay A Gandolfi; Shirin R Hasan; Marty Bartholdi; Anne E Cress
Journal:  Eur J Cell Biol       Date:  2005-03       Impact factor: 4.492

3.  GSTP1 CpG island hypermethylation is responsible for the absence of GSTP1 expression in human prostate cancer cells.

Authors:  X Lin; M Tascilar; W H Lee; W J Vles; B H Lee; R Veeraswamy; K Asgari; D Freije; B van Rees; W R Gage; G S Bova; W B Isaacs; J D Brooks; T L DeWeese; A M De Marzo; W G Nelson
Journal:  Am J Pathol       Date:  2001-11       Impact factor: 4.307

4.  Immunohistochemical expression of pi class glutathione S-transferase in the basal cell layer of benign prostate tissue following chronic treatment with finasteride.

Authors:  R Montironi; R Mazzucchelli; R Pomante; D Thompson; V Duval da Silva; L Vaught; P H Bartels
Journal:  J Clin Pathol       Date:  1999-05       Impact factor: 3.411

5.  Expression of pi-class glutathione S-transferase: two populations of high grade prostatic intraepithelial neoplasia with different relations to carcinoma.

Authors:  R Montironi; R Mazzucchelli; D Stramazzotti; R Pomante; D Thompson; P H Bartels
Journal:  Mol Pathol       Date:  2000-06

6.  Identification of glutathione sulfotransferase-pi (GSTP1) as a new resveratrol targeting protein (RTP) and studies of resveratrol-responsive protein changes by resveratrol affinity chromatography.

Authors:  Tze-Chen Hsieh; Zhirong Wang; Haiteng Deng; Joseph M Wu
Journal:  Anticancer Res       Date:  2008 Jan-Feb       Impact factor: 2.480

7.  GSTPi-positive tumour microenvironment-associated fibroblasts are significantly associated with GSTPi-negative cancer cells in paired cases of primary invasive breast cancer and axillary lymph node metastases.

Authors:  B Chaiwun; N Sukhamwang; H Trakultivakorn; B Saha; L Young; D Tsao-Wei; W Y Naritoku; S Groshen; C R Taylor; S A Imam
Journal:  Br J Cancer       Date:  2011-09-06       Impact factor: 7.640

Review 8.  Glutathione S-conjugates as prodrugs to target drug-resistant tumors.

Authors:  Emma E Ramsay; Pierre J Dilda
Journal:  Front Pharmacol       Date:  2014-08-11       Impact factor: 5.810

9.  Copper as a target for prostate cancer therapeutics: copper-ionophore pharmacology and altering systemic copper distribution.

Authors:  Delphine Denoyer; Helen B Pearson; Sharnel A S Clatworthy; Zoe M Smith; Paul S Francis; Roxana M Llanos; Irene Volitakis; Wayne A Phillips; Peter M Meggyesy; Shashank Masaldan; Michael A Cater
Journal:  Oncotarget       Date:  2016-06-14

10.  GSTP1 Ile105Val polymorphism and prostate cancer risk: evidence from a meta-analysis.

Authors:  Bingbing Wei; You Zhou; Zhuoqun Xu; Jun Ruan; Huan Cheng; Ming Zhu; Qiang Hu; Ke Jin; Zhiqiang Yan; Deqi Zhou; Feng Xuan; Hongyi Zhou; Zhirong Wang; Xing Huang; Qiang Wang
Journal:  PLoS One       Date:  2013-08-19       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.